Your shopping cart is currently empty

SHR0687 is a Highly Potent KOR Agonist. SHR0687 showed excellent selectivity over other opioid receptors, such as MOR and DOR. In addition, SHR0687 displayed favorable PK profiles across species, as well as robust in vivo efficacy in a
rat carrageenan-induced pain model. Notably, SHR0687 exhibited negligible blood−brain barrier penetration, which was meaningful in minimizing CNS-related side effects.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $2,420 | 10-14 weeks | 10-14 weeks | |
| 50 mg | $3,180 | 10-14 weeks | 10-14 weeks | |
| 100 mg | $4,300 | 10-14 weeks | 10-14 weeks |
| Description | SHR0687 is a Highly Potent KOR Agonist. SHR0687 showed excellent selectivity over other opioid receptors, such as MOR and DOR. In addition, SHR0687 displayed favorable PK profiles across species, as well as robust in vivo efficacy in a rat carrageenan-induced pain model. Notably, SHR0687 exhibited negligible blood−brain barrier penetration, which was meaningful in minimizing CNS-related side effects. |
| Molecular Weight | 720.94 |
| Formula | C39H60N8O5 |
| Cas No. | 2168573-03-1 |
| Smiles | C([C@H](NC([C@H](NC([C@@H](CC1=CC=CC=C1)NC(CNC[C@H](C)C2=CC=CC=C2)=O)=O)CC(C)C)=O)CCCCN)(=O)N3CCC(NC(NC)=O)CC3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.